文献速递心脑血管急症重症综合管理与镇静镇痛

美索比妥用于急诊科电复律程序性镇静

Methohexital for procedural sedation of cardioversions in the emergency department.
PubMed 文献 · Am J Emerg Med · 2022-05-25
一句话结论单中心回顾性研究显示,美索比妥用于急诊电复律镇静时,达到目标Aldrete评分时间、离院时间及需干预的血流动力学变化与丙泊酚和依托咪酯相似。

该单中心回顾性研究纳入2015年2月1日至2020年7月31日在急诊科接受电复律程序性镇静的成人患者,比较美索比妥、丙泊酚和依托咪酯作为初始镇静剂的效果。每组50例,共150例。主要终点为从初始给药到达到目标Aldrete评分的时间,三组中位数分别为美索比妥10.5分钟、丙泊酚12.0分钟、依托咪酯11.0分钟(p=0.863)。次要终点为从给药到急诊离院时间(n=105),三组均值分别为90.4、89.0和94.0分钟(p=0.897)。需干预的血流动力学变化组间无差异。结论认为美索比妥与丙泊酚和依托咪酯疗效和安全性相似。

要点

  • 美索比妥组达到目标Aldrete评分中位时间10.5分钟(IQR 7-18.5),丙泊酚组12.0分钟(IQR 9-16.8),依托咪酯组11.0分钟(IQR 8-15),p=0.863。
  • 美索比妥组急诊离院平均时间90.4±40.4分钟,丙泊酚组89.0±57.4分钟,依托咪酯组94.0±42.5分钟(n=105),p=0.897。
  • 三组间需干预的血流动力学变化无差异。
  • 研究为单中心回顾性设计,每组50例,结论需结合原文局限性解读。

适用人群与场景

  • 2015年2月1日至2020年7月31日在急诊科接受电复律程序性镇静的成人患者。
  • 纳入患者以美索比妥、丙泊酚或依托咪酯作为初始镇静剂。

研究设计与关键结果

  • 研究类型:单中心、回顾性研究;样本量:150例电复律操作,每组50例;人群:急诊科接受电复律程序性镇静的成人患者;干预与对照:美索比妥 vs 丙泊酚 vs 依托咪酯作为初始镇静剂。
  • 主要终点:从初始镇静剂给药到达到目标Aldrete评分的中位时间(分钟),美索比妥10.5(IQR 7-18.5),丙泊酚12.0(IQR 9-16.8),依托咪酯11.0(IQR 8-15),p=0.863。
  • 关键次要终点:从镇静剂给药到急诊离院平均时间(分钟,n=105),美索比妥90.4±40.4,丙泊酚89.0±57.4,依托咪酯94.0±42.5,p=0.897。
  • 安全性终点:需干预的危重血流动力学变化,组间无差异。
  • 结论:美索比妥用于急诊电复律程序性镇静时,疗效和安全性特征与丙泊酚和依托咪酯相似。

证据类型、等级与局限

  • 证据类型:单中心、回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,美索比妥用于急诊电复律程序性镇静时,疗效和安全性特征与丙泊酚和依托咪酯相似;该结论来自单中心回顾性研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Procedural sedation for electrical cardioversion is a common practice in the emergency department (ED). Ideal sedative properties for this procedure are a short half-life and minimal hemodynamic effects. There is limited literature examining methohexital for this use.

OBJECTIVE: To compare the use of methohexital to propofol and etomidate for procedural sedation for electrical cardioversions in the ED.

METHODS: This was a single-center, retrospective study of adult patients who underwent procedural sedation for electrical cardioversion in the ED between February 1, 2015 and July 31, 2020. Included patients received methohexital, propofol, or etomidate as an initial sedative agent in the ED. The primary outcome was time from initial dose of sedative to goal Aldrete score. The main secondary outcome was time from sedative agent to ED discharge. The safety outcome was the occurrence of a critical hemodynamic change requiring intervention. Outcomes were assessed using a single-factor ANOVA analysis.

RESULTS: One-hundred and fifty cardioversion encounters were included with 50 encounters per cohort. The median (IQR) time (minutes) to goal Aldrete score was 10.5 (7-18.5) for methohexital, 12.0 (9-16.8) for propofol, and 11.0 (8-15) for etomidate (p = 0.863). Mean (SD) time (minutes) to discharge from the ED (n = 105) was 90.4 ± 40.4 for methohexital, 89.0 ± 57.4 for propofol, and 94.0 ± 42.5 for etomidate (p = 0.897). No difference was seen between the groups regarding hemodynamic changes requiring intervention.

CONCLUSION: Methohexital was found to have a similar efficacy and safety profile when compared to propofol and etomidate when used as procedural sedation for cardioversions in the ED.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Bauer J, Beauchamp L, Pavich E, et al. Methohexital for procedural sedation of cardioversions in the emergency department. Am J Emerg Med. 2022. PMID: 35636047. doi:10.1016/j.ajem.2022.05.036

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。